Low-Dose CETP Inhibitor Composition for Better Patient Compliance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CETP inhibitors face challenges such as high dosages leading to swallowing difficulties, patient compliance issues, side effects, and inter-subject pharmacokinetic variability, with anacetrapib requiring several years to eliminate from the body.
Innovation Solution
A compound (Compound A) or its pharmaceutically acceptable salts, administered in doses ranging from 1 to 25 mg per day, effectively inhibits CETP with near-complete inhibition at lower doses, showing no significant side effects and maintaining efficacy without prolonged residual effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of CETP inhibitors (e.g., anacetrapib) are administered to achieve near-complete CETP inhibition, then cardiovascular efficacy is improved, but patient compliance deteriorates due to swallowing difficulties and side effects
Solution Approach 1:
The patent changes the chemical structure parameters of CETP inhibitors to achieve high potency at low doses. Compound A and its analogs are designed with specific molecular modifications that increase their affinity for CETP, enabling near-complete inhibition at doses of 1-25 mg daily, thereby maintaining cardiovascular efficacy while improving patient compliance.
Solution Approach 2:
The patent segments the high-dose regimen into multiple low-dose administrations. By dividing the total daily dose into smaller increments (e.g., 1-25 mg per day), the formulation reduces the burden of taking large pills while maintaining cumulative therapeutic effect, thus improving swallowing ease and patient compliance.
2Reliability
If high doses of CETP inhibitors are administered to achieve near-complete CETP inhibition, then cardiovascular efficacy is improved, but adverse effects increase
Solution Approach 1:
The patent modifies chemical structure parameters to achieve dose-sparing effects. Compound A and its analogs exhibit enhanced potency with lower daily doses (1-25 mg), which reduces the exposure to off-target effects while maintaining on-target CETP inhibition. This structural optimization decouples efficacy from toxicity.
Solution Approach 2:
The patent employs shorter-acting CETP inhibitor molecules that are rapidly cleared from the body. By designing compounds with appropriate pharmacokinetic profiles (shorter half-lives), the patent reduces cumulative exposure and allows for quicker recovery if adverse effects occur, while maintaining effective CETP inhibition during the dosing interval.
3Reliability
If high doses of CETP inhibitors are administered to achieve near-complete CETP inhibition, then cardiovascular efficacy is improved, but tablet size increases making swallowing difficult
Solution Approach 1:
The patent changes the dosage parameter from high (100-200 mg) to low (1-25 mg) through chemical structure optimization. Compound A and its analogs achieve comparable or superior CETP inhibition at these reduced doses, directly translating to smaller, more swallowable tablet formulations without compromising cardiovascular efficacy.
4Reliability
If high doses of CETP inhibitors are administered to achieve near-complete CETP inhibition, then cardiovascular efficacy is improved, but inter-subject pharmacokinetic variability increases
Solution Approach 1:
The patent optimizes pharmacokinetic parameters through chemical structure modification. Compound A and its analogs are designed with improved metabolic stability, protein binding characteristics, and clearance profiles that reduce inter-subject variability. This allows for more predictable drug exposure and consistent CETP inhibition across different patient populations at low doses.
Data Source
AI summary
The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor:(Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.